ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Gerald, and I'll be your host for today.
Acadia Pharmaceuticals Inc (ACAD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 42,896,690 | $925,281,603 | +1% | 8.98% |
| 2. | Point72 Asset Management Steve Cohen | 3,172,511 | $68,431,062 | -32% | 0.13% |
| 3. | Citadel Investment Group Ken Griffin | 3,012,696 | $64,983,853 | +923% | 0.01% |
| 4. | Palo Alto Investors William Leland Edwards | 2,563,209 | $55,288,418 | -4% | 11.76% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,969,711 | $42,486,667 | +497% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.65 | 259,109 | $6,646,145.85 | 39,317,673 | 2023-05-24 | Filing | |
| $25.65 | 24,113 | $618,498.45 | 3,610,443 | 2023-05-24 | Filing | |
| $25.51 | 28,878 | $736,787.52 | 39,058,564 | 2023-05-24 | Filing | |
| $25.51 | 2,688 | $68,581.09 | 3,586,330 | 2023-05-24 | Filing | |
| $25.27 | 218,171 | $5,513,682.96 | 39,029,686 | 2023-05-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.78 | 14,446 | $314,633.88 | 15,095 | 2025-06-04 | Filing | |
| $20.00 | 2,000 | $40,000.00 | 20,395 | 2025-05-16 | Filing | |
| $25.00 | 2,000 | $50,000.00 | 22,395 | 2025-05-16 | Filing | |
| $25.00 | 2,000 | $50,000.00 | 62,130 | 2025-05-16 | Filing | |
| $14.60 | 1,327 | $19,374.20 | 23,526 | 2025-05-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,652,416 | $445,472,612 | 0.01% | |
| 2. | 15,264,240 | $329,249,657 | 0.01% | |
| 3. | 8,995,547 | $194,033,949 | 2.76% | |
| 4. | 6,178,044 | $133,260,409 | 0% | |
| 5. | 4,111,247 | $88,679,611 | 0.01% |
News See All
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
US Appeals Court Confirms Patent Validity of Acadia's Parkinson's Medication
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
BofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)'s Price Target To $23, Maintains Neutral Rating
[caption id="attachment_1202489" align="aligncenter" width="1456"] A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical...
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday
We recently published a list of 10 Surprising Stocks That Skyrocketed Today. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Lauren Cannon, and I'll be your coordinator for today.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
12 Best Nasdaq Stocks Under $20 to Buy Now
The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13.